Altimmune, Inc.

NasdaqGM ALT

Altimmune, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -3,857.69%

Altimmune, Inc. Gross Profit Margin is -3,857.69% for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Altimmune, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -1,629.67%, a 13.67% change year over year.
Altimmune, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,887.62%, a -249.77% change year over year.
Altimmune, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -539.67%, a -315.77% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: ALT

Altimmune, Inc.

CEO	Dr. Vipin K. Garg Ph.D.
IPO Date	May 26, 2017
Location	United States
Headquarters	910 Clopper Road
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Key trends

Past 5 years